High Heated Humidity in Stem Cell Transplant
Phase 2
Recruiting
- Conditions
- Autologous Stem Cell Transplant
- Interventions
- Device: Airvo
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 90
- Registration Number
- NCT05358262
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Steroid Sparing in Immune Related Hepatitis (irH)
Not Applicable
Not yet recruiting
- Conditions
- Hepatitis Immune
- Interventions
- Other: Early initiationOther: Active Surveillance
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 55
- Registration Number
- NCT05345847
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
Phase 2
Not yet recruiting
- Conditions
- Breast Cancer Triple Negative
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT05128734
- Locations
- 🇨🇦
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer
Phase 2
Recruiting
- Conditions
- Anal Canal Cancer
- Interventions
- Radiation: chemo-radiation treatment
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 45
- Registration Number
- NCT05040815
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Prognostic Indicators for Radiation-induced Breast Fibrosis
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Radiation: Breast Cancer Radiotherapy
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 27
- Registration Number
- NCT05031065
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Exercise and Compression for Lymphedema
Not Applicable
Active, not recruiting
- Conditions
- Breast Cancer Related Lymphedema
- Interventions
- Device: Adjustable Compression (AC) garment, worn during exerciseDevice: Compression sleeve, worn during exerciseDevice: Compression sleeve, daytime wearBehavioral: Home exercise programBehavioral: Decongestive Progressive Resistance Exercise program
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT05022823
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys
Not Applicable
Recruiting
- Conditions
- Colorectal CancerBreast Cancer
- Interventions
- Other: Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 128
- Registration Number
- NCT04990895
- Locations
- 🇨🇦
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- Radiation: Dose-escalated adaptive radiotherapyDrug: Chemotherapy
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 31
- Registration Number
- NCT04952480
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 2
Completed
- Conditions
- Gastroesophageal Junction AdenocarcinomaAdvanced Gastric Carcinoma
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 7
- Registration Number
- NCT04808791
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 60
- Registration Number
- NCT04765098
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath